Eisai's FY3/29 Profit Target Below Expectations; Rising Costs Drag on Earnings
AI summary card
Eisai's FY3/29 Profit Target Below Expectations; Rising Costs Drag on Earnings
Goldman Sachs maintains a Neutral rating on Eisai, viewing its FY3/29 core operating profit target of JPY 90 billion as below expectations, primarily due to the cost of sales ratio rising to 30%.
- FY3/29 sales target of JPY 1 trillion is largely in line with expectations
- Core operating profit target of JPY 90 billion is below Goldman Sachs' expectation of JPY 108.3 billion
- Cost of sales ratio is expected to rise from 23.7% in FY3/27 to 30%
- Alzheimer's drug Leqembi sales target is JPY 300 billion
- Cancer drug Lenvima sales are expected to decline to JPY 250 billion due to patent expiration
- Maintaining a Neutral rating with a 12-month target price of JPY 4,750
Report interpretation
Overview
Goldman Sachs interprets Eisai's first Corporate Strategy IR Day, believing that in the company's announced three-year plan through FY3/29 (ending March 2029), the sales target meets expectations, but the core operating profit target falls short, primarily due to margin pressure from changes in the product sales mix. The report maintains a Neutral rating, focusing on the impact of Leqembi sales expansion on profit margins.
Core views
Regarding sales targets, Eisai has set FY3/29 sales at JPY 1 trillion (including over JPY 300 billion from Leqembi), which is largely flat compared to Goldman Sachs' expectation of JPY 970 billion. However, the core operating profit target of JPY 90 billion is significantly lower than Goldman Sachs' expectation of JPY 108.3 billion, mainly because the cost of sales ratio (CoGS) is rising from 23.7% in FY3/27 to 30%. Changes in product mix are the primary driver of rising costs: High-margin cancer drug Lenvima sales are expected to decline from JPY 284.6 billion to JPY 250 billion due to European patent expiration and US IRA price reductions; while Leqembi sales are growing to JPY 300 billion, its higher production costs drag down the overall gross margin. The insomnia drug Dayvigo, with a sales target of JPY 100 billion, is also one of the growth drivers. R&D focuses on neuroscience and oncology: Before FY3/29, the company aims to advance the anti-tau antibody Etalanetug and the orexin-2 receptor agonist Ledasorexton into the filing stage, while deploying a pipeline of minimal residual disease (MRD)-targeted drugs in the oncology field. Capital allocation prioritizes growth investments, with operating cash flow used for R&D, capital expenditures, and shareholder returns, while financing cash flow supports product licensing and M&A.
Analysis framework
Goldman Sachs derives a target price of JPY 4,750 using a DCF valuation model (12-year period, 6% WACC, 0% terminal growth rate). The analytical logic centers on the impact of product mix changes on profit margins: by comparing company targets with market consensus, it quantifies the drag on earnings from differences in the cost of sales ratio. It also tracks key catalysts, such as pricing and market penetration changes for the Leqembi subcutaneous injection formulation (SC-AI), for which the PDUFA date for label expansion to initial therapy is August 24, 2026.
Methodology notes
DCF Discounted Cash Flow Model
Calculates intrinsic value by forecasting the company's future free cash flows and discounting them to present value. This report assumes a 12-year forecast period, a 6% weighted average cost of capital (WACC), and a 0% terminal growth rate, reflecting expectations for stable long-term growth for Eisai.
Impact of Product Sales Mix Changes on Gross Margin
Gross margins vary significantly across products; low-margin products with high sales shares (such as Leqembi) will drag down overall profit margins. The research report quantifies the impact of product mix changes on profit targets by breaking down revenue contributions and cost structures for each product.
Distinction Between Core Operating Profit and Non-Recurring Income
The company emphasizes that growth relies on organic business (non-one-time income); analysis must exclude non-recurring gains and losses to focus on sustainable profitability. The research report uses core operating profit as a key evaluation metric.
Key data
- FY3/29 Sales TargetJPY 1 trillionIncludes over JPY 300 billion from Leqembi, close to Goldman Sachs' expectation of JPY 970 billion
- FY3/29 Core Operating Profit TargetJPY 90 billionBelow Goldman Sachs' expectation of JPY 108.3 billion and market consensus of JPY 100.8 billion
- Cost of Sales Ratio (CoGS)30%Significantly higher than 23.7% in FY3/27, exceeding Goldman Sachs' expectation of 24.1%
- Leqembi Global Sales TargetJPY 300 billionAlzheimer's treatment drug, a major growth driver
- Lenvima Sales ExpectationJPY 250 billionDeclining from previous levels due to patent expiration and price reductions
- 12-Month Target PriceJPY 4,750Based on DCF model, maintaining a Neutral rating
Impact & implications
The research report believes that although sales targets indicate good growth prospects, deteriorating profitability may suppress the stock price in the short term. Market attention will shift to the actual impact of Leqembi's new formulation pricing strategy and market penetration on profit margins. If cost control falls short of expectations, earnings forecasts may be further downgraded.
Risks
- Key drug sales falling short of expectations
- Drug development suspension or delays
- Changes in product assessments
- Negative news related to Alzheimer's drugs
- Negative news on Lenvima affecting Merck payment expectations
What to watch
- Initial therapy pricing for the Leqembi subcutaneous injection formulation (SC-AI)
- Margin changes accompanying Leqembi market penetration
- PDUFA label expansion approval results on August 24, 2026